Zosano Pharma ™, Inc., is a private pharmaceutical company founded in October 2006 and is focused on creating better products with our innovative drug delivery technology.  Our lead program, parathyroid hormone (PTH) transdermal microprojection delivery system has finalized a Phase 2 clinical trial for treating severe osteoporosis.  Zosano’s objective is to discover and develop therapeutic drug candidates which address large unmet medical needs or have a significant potential for commercialization.

The Company is a Johnson and Johnson Internal Ventures spin-out from the ALZA Corporation, and is funded with $90 million by the following venture capital firms:

New Enterprise Associates (NEA)

Nomura Phase4 Ventures

HBM BioVentures

ProQuest Investments.

Our Technology 

Zosano’s Macroflux^® transdermal microprojection delivery system provides convenient needle-free administration with room temperature stability for various therapeutic peptides, proteins, small molecules and vaccines.   

Our transdermal system has been clinically tested in over 300 subjects with four different therapeutic compounds.  Zosano Pharma’s lead program, parathyroid hormone (hPTH 1-34, teraparatide), has finished a Phase 2 development to treat post menopausal women with severe osteoporosis who are at a high risk of bone fracture.  We completed enrollment in November 2007 and will report results of this trial during the second half of 2008. 

Our Regulatory strategy is pursuing a 505b2 approval which leverages existing PTH safety and efficacy data of the marketed product FORTEO^®.   But unlike Lilly’s FORTEO which is an injection, our needle-free patch should be more convenient and acceptable for elderly women with osteoporosis.   

Zosano is actively exploring and developing its own additional proprietary pipeline of products as well as pursuing other product partnership programs with various pharmaceutical companies.  

In addition to our system’s needle-free convenience, our room temperature stability will be an important differentiating feature.  Such room temperature stability may remove the need for refrigeration and potentially eliminate cold chain distribution around the globe.  

Zosano technology can deliver potent peptides, small water soluble molecules, biopharmaceuticals and vaccines with good non-refrigerated stability and needle-free convenience.  Zosano has established a formidable intellectual property position in this arena with 15 patent families and 42 pending patents. 

Zosano is headquartered in Fremont, California.  Our team is made up of strong scientists and business professionals with decades of experience leading successful pharmaceutical organizations.

Based on a small patch and applicator, Zosano’s technology combines rapid drug delivery and good bioavailability with a convenient needle-free administration and a stable room temperature product.

The company’s leading program, a PTH transdermal microprojection patch for osteoporsis, is currently in Phase 2. Other programs are being explored and partnership opportunities also exist.